NCT00648089

EPOMI Study: ErythroPOietin in Myocardial Infarction

ErythroPOietin in Myocardial Infarction

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 110 (actual)
• Sponsor: University Hospital, Angers · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

EPOMI is a randomized, open-label, parallel phase II clinical study that will evaluate the effects of a single erythropoietin administration on infarct size and cardiac remodeling in patients with acute myocardial infarction. Eligible patients will be randomly assigned to receive conventional therapy and single infusion of 1000U/kg of epoetin beta or conventional therapy alone. Infarct size and cardiac remodeling parameters will be assessed by cardiac magnetic resonance imaging (MRI) within 3-7 days of the randomization and repeated 3 months later.

Conditions

• Myocardial Infarction

Interventions

Type	Name	Description
DRUG	EPO	Single Injection of 1000 U/kg Erythropoietin beta IV immediately after primary PCI

Timeline

• Start date: 2008-04-01
• Primary completion: 2010-12-01
• Completion: 2010-12-01
• First posted: 2008-04-01
• Last updated: 2011-01-31

Locations

2 sites across 1 country: France